The funding was led by MDV-Mohr Davidow Ventures and included Bessemer Venture Partners, Physic Ventures and Northgate Capital.

In addition to Sue Siegel, MDV Partner and On-Q-ity board member, Steve Kraus from Bessemer Venture Partners and Dion Madsen from Physic Ventures will join the On-Q-ity board of directors.

Mara Aspinall, president and CEO of On-Q-ity, said: "We will enable physicians to confidently choose effective therapy and then actively monitor their patients' treatment response or resistance. By using CTCs and predictive DNA repair biomarkers, we can help quickly determine if a therapy is working and reduce the cost as well as the loss of critical time associated with ineffective treatments. Through ongoing personalized diagnosis, we hope to improve patient care and, ultimately, increase survival rates."

A service of YellowBrix, Inc.